Christoph Zielinski


Professor Zielinski is Director of the Vienna Cancer Center of the Vienna Hospital Association and the Medical University Vienna, Austria. He is President of the Central European Cooperative Oncology Group.

Professor Zielinski completed his medical training at the University Hospital Vienna and began his career with a position as a research fellow at the Cancer Research Center at Tufts University, Boston, USA. His recent clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast and lung cancer research and treatment and development of targeted drugs. He has published env. 450 original papers and reviews in peer-review journals and many books including the “State of Oncology 2013” published together with Peter Boyle et al. by IPRI. He is member of the editorial board of numerous peer review journals. In 2013, Professor Zielinski received a “Dr. h.c.” degree from Titu Maiorescu University in Bucharest.

Professor Zielinski is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO).

Prof. Zielinski serves on a series of committees of the European Society of Medical Oncology (ESMO) including its Executive Committee in which he is a member for 2014. He was also Local Officer for the ESMO Congress 2012 in Vienna, Austria.

Christiane Thallinger

Chief Executive Officer

Specialist in Dermatology and Venerology
MBA of General Management

Christiane Thallinger is a specialist in Dermatology and Venerology and Program Director of the Extravasation and Cutaneous Side Effects in Oncology Unit at the Clinical Division of Oncology, Department of Medicine I, Medical University Vienna, Austria.

In addition, she serves as Chief Managing Officer of the Central European Cooperative Oncology Group (CECOG,

Christiane Thallinger has completed her medical training at the University Hospital Vienna and has spent a one-year sabbatical at the University of California San Diego on animal models in immunological skin diseases.

Her recent clinical research activities cover a wide range of cancer therapies, with particular focus on the management of cutaneous side effects of cancer treatments as well as the performance and administration of clinical trials within CECOG.

Finally, she is director for quality management at the Department of Medicine I at Medical University Vienna.

Dr. Thallinger has published more than 50 papers in peer-review journals.

Ursula Fischer

Director Academy

Ursula Fischer, BA, joined CECOG in 2000.

Her main tasks include the organization of Skeletal Care Meetings, Consensus Conferences and EGFR Workshops. She also assists in editorial issues such as the submission of abstracts, manuscripts and poster preparations. In her function as Clinical Research Associate she closely cooperates with investigators/sites in ongoing clinical trials.

In 2017, she was promoted to the position as Director of CECOG Academy.

Barbara Schaljo-Kapp

Project Manager

Barbara Schaljo-Kapp made her PhD in the field of Immunobiology. She is clinical project manager since 2008 and operated since 2011 on an international level with main focus on Central Eastern Europe.

As clinical project manager Barbara Schaljo-Kapp is responsible for planning, executing, managing and reporting on clinical studies. She ensures the timeliness and quality of study deliverables in accordance with SOPs, ICH/GCP guidelines and local regulations. She provides a single point of contact at the study level for Local Operating Countries staff and at country level for Global Study Management.

In 2017 she joined the CECOG Academy to support the TIGER project.